Skip to main content

PTPN11 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human PTPN11 (SHP2) knockout HEK-293T cell line (AB266450), expandable thumbnail
  • Western blot - Human PTPN11 (SHP2) knockout HEK-293T cell line (AB266450), expandable thumbnail
  • Cell Culture - Human PTPN11 (SHP2) knockout HEK-293T cell line (AB266450), expandable thumbnail
  • Sanger Sequencing - Human PTPN11 (SHP2) knockout HEK-293T cell line (AB266450), expandable thumbnail
  • Sanger Sequencing - Human PTPN11 (SHP2) knockout HEK-293T cell line (AB266450), expandable thumbnail

Key facts

Cell type
HEK-293T
Species or organism
Human
Tissue
Kidney
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1

Alternative names

BPTP3, JMML, METCDS, MGC14433, OTTHUMP00000166107, OTTHUMP00000166108, PTN11_HUMAN, PTP-1D, PTP-2C, PTPN11, Protein tyrosine phosphatase 2, Protein tyrosine phosphatase non receptor type 11, Protein-tyrosine phosphatase 1D, Protein-tyrosine phosphatase 2C, SAP-2, SH-PTP2, SH-PTP3, SH2 domain containing protein tyrosine phosphatase 2, SHP-2, Tyrosine-protein phosphatase non-receptor type 11

Recommended products

PTPN11 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1.

Key facts

Cell type
HEK-293T
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1
Concentration
Loading...

Properties

Gene name
PTPN11
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

SHP2 also known as PTPN11 is a protein tyrosine phosphatase with a molecular mass of approximately 68 kDa. It is expressed in various tissues including the heart liver and immune cells. SHP2 belongs to the non-receptor class of protein tyrosine phosphatases and plays a critical role in cell signaling by acting as a regulator of signal transduction processes. SHP2 mediates these processes by dephosphorylating specific phosphotyrosine residues on target proteins influencing various cellular functions like proliferation differentiation and survival.

Biological function summary

The role of SHP2 extends to involvement in several signaling cascades such as the Ras/MAPK and PI3K/AKT pathways. It functions as an essential component within protein complexes that facilitate cell communication and response to external signals. The protein modulates growth factor signaling and cytokine signaling highlighting its significance in normal cell function and development. SHP2's statement in signaling processes makes it an important regulator of cellular dynamics.

Pathways

SHP2 participates in the Ras/MAPK and PI3K/AKT signaling pathways which are important for regulating cell growth survival and differentiation. Within these pathways SHP2 interacts with various signaling molecules including Grb2 Sos and Gab family adaptors. These interactions coordinate cellular responses to growth factors and other extracellular cues ensuring proper pathway activation and control. By serving as a critical mediator SHP2 integrates signals that are necessary for appropriate cellular outcomes.

Associated diseases and disorders

SHP2 is associated with several conditions such as Noonan syndrome and various cancers. Mutations in the PTPN11 gene which encodes SHP2 often result in aberrant signaling that leads to developmental anomalies or tumorigenesis. In Noonan syndrome the mutated SHP2 protein results in disrupted Ras/MAPK pathway signaling. As for cancers SHP2 is often found to be overactive leading to enhanced cell proliferation and survival. In these contexts SHP2 is interconnected with other proteins like RAS and RAF which also contribute to oncogenic pathway activation and disease progression.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

6 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com